Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions

In the last years due to development of molecular methods a substantial progress in understanding of genetic associations with drug effects in many clinical disciplines has been observed. The efforts to define the role of genetic polymorphisms in optimizing pharmacotherapy of Parkinson’s disease (PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Droździk, Marek, Białecka, Monika, Kurzawski, Mateusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924251/
https://www.ncbi.nlm.nih.gov/pubmed/24532988
http://dx.doi.org/10.2174/1389202914666131210212521
_version_ 1782303722538270720
author Droździk, Marek
Białecka, Monika
Kurzawski, Mateusz
author_facet Droździk, Marek
Białecka, Monika
Kurzawski, Mateusz
author_sort Droździk, Marek
collection PubMed
description In the last years due to development of molecular methods a substantial progress in understanding of genetic associations with drug effects in many clinical disciplines has been observed. The efforts to define the role of genetic polymorphisms in optimizing pharmacotherapy of Parkinson’s disease (PD) were also undertaken. So far, some promising genetic loci for PD treatment were determined. In the review pharmacogenetic aspects of levodopa, dopamine agonists and COMT inhibitors are discussed.
format Online
Article
Text
id pubmed-3924251
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-39242512014-06-01 Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions Droździk, Marek Białecka, Monika Kurzawski, Mateusz Curr Genomics Article In the last years due to development of molecular methods a substantial progress in understanding of genetic associations with drug effects in many clinical disciplines has been observed. The efforts to define the role of genetic polymorphisms in optimizing pharmacotherapy of Parkinson’s disease (PD) were also undertaken. So far, some promising genetic loci for PD treatment were determined. In the review pharmacogenetic aspects of levodopa, dopamine agonists and COMT inhibitors are discussed. Bentham Science Publishers 2013-12 2013-12 /pmc/articles/PMC3924251/ /pubmed/24532988 http://dx.doi.org/10.2174/1389202914666131210212521 Text en ©2013 Bentham Science Publishers http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Droździk, Marek
Białecka, Monika
Kurzawski, Mateusz
Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
title Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
title_full Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
title_fullStr Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
title_full_unstemmed Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
title_short Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
title_sort pharmacogenetics of parkinson’s disease – through mechanisms of drug actions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924251/
https://www.ncbi.nlm.nih.gov/pubmed/24532988
http://dx.doi.org/10.2174/1389202914666131210212521
work_keys_str_mv AT drozdzikmarek pharmacogeneticsofparkinsonsdiseasethroughmechanismsofdrugactions
AT białeckamonika pharmacogeneticsofparkinsonsdiseasethroughmechanismsofdrugactions
AT kurzawskimateusz pharmacogeneticsofparkinsonsdiseasethroughmechanismsofdrugactions

Ejemplares similares